Topic

Articles

The report indicates a rise in biotech funding and subsequent growth for pharma contract services.

CPHI Annual Report: VC Capital Investment and Contract Services Growth in 2024

Bettersize US showcases their BeNano Series, Bettersizer 2600, and BetterPyc 380 instruments at the AAPS 2023 PharmSci 360 event. 

Bettersize Unveils New Capabilities at AAPS 2023 PharmSci 360

Videos

Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the important components of nitrosamine impurities from a manufacturing point of view as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."

Crucial Points from a Manufacturing Perspective (PDA/FDA Joint Regulatory Conference 2023)

Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the recent findings of nitrosamine impurities in human drugs as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."

The Recent Discoveries of Nitrosamine Impurities (PDA/FDA Joint Regulatory Conference 2023)

The Start-Up Market at CPHI Barcelona will bring together 27 start-ups, innovators, and small enterprises from across the pharma landscape.

Innovative Start-Ups at CPHI Barcelona

Sherma Ellis Daal, brand director, Pharma at Informa Markets, gives a preview of CPHI Barcelona 2023. 

Welcome to CPHI Barcelona

Bikash Chatterjee is President and Chief Technology Officer at Pharmatech Associates USA.

CPHI’s Annual Report predicts huge impact of AI on drug development and manufacturing.

The Impact of AI on Pharma

Humberto Vega, PhD, Executive Director, Bristol Myers Squibb, discusses the requirements needed to be successful in global cell therapy as a part of his session, "Successfully Navigating Global Cell Therapy Requirements."

Global Cell Therapy Requirements Need Thorough Understanding

Humberto Vega, PhD, Executive Director, Bristol Myers Squibb, discusses the journey from clinical to commercial cell therapies as a part of his session, "Successfully Navigating Global Cell Therapy Requirements."

The Challenges of the Journey from Clinical to Commercial Cell Therapies

Bassem Gayed, PhD, Senior Technical Director of CAR-T Process Engineering, Manufacturing Science & Technology at Bristol Myers Squibb, discusses the importance of CAR-T as a modality.

Conferences